Stock report · Delisted · Nasdaq
Unity Biotechnology Inc (UBX)
0.16USD Delisted Final close · Jul 9, 2025
UBX no longer trades. Unity Biotechnology was delisted from the Nasdaq in July 2025.
All prices on this page are historical. The last trade was on July 9, 2025, at $0.16.
UBX stock price history
Final trading statistics
- Final close
- $0.16
- Final trading day
- Jul 9, 2025
- Market cap at delisting
- $2.75M
- Shares outstanding
- 17.21M
- Final 52-week range
- $0.10 – $3.10
- Avg. volume (final 3 mo.)
- 723,423
- All-time high
- $229.70 · Sep 2018
- All-time low
- $0.16 · Jul 2025
- Return since IPO
- -99.9%
- Beta
- 1.06
- Book value / share
- −$0.01
- Price / book
- -13.33
About Unity Biotechnology Inc
Unity Biotechnology, Inc. researched and developed therapies meant to slow, halt or reverse diseases of aging. Its lead candidate, UBX1325, was in Phase 2 for age-related eye diseases such as diabetic macular edema, age-related macular degeneration and diabetic retinopathy.
Other programs included UBX1967 for eye diseases, UBX2048, a Tie2/VEGF bispecific, UBX2050, an anti-Tie2 agonist antibody for eye disease, and UBX2089, an a-Klotho hormone candidate for several neurology uses.
Known as Forge, Inc. until January 2015, the company was incorporated in 2009 and based in South San Francisco. Its stock was delisted from the Nasdaq in July 2025, with the last trade on July 9, 2025 at $0.16.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- South San Francisco, CA
- Employees
- 16
- IPO date
- May 3, 2018
- Delisted
- July 9, 2025
- SEC CIK
- 1463361
Unity Biotechnology financials before the delisting
The last 5 fiscal years Unity Biotechnology reported as a public company, fiscal year ending December.
UBX revenue and net income
UBX earnings per share
UBX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | −$26.0M | −$1.53 |
| FY2023 | $0.00 | −$39.9M | −$2.55 |
| FY2022 | $236.0K | −$57.7M | −$7.06 |
| FY2021 | $4.78M | −$60.0M | −$10.90 |
| FY2020 | $0.00 | −$91.9M | −$18.10 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Unity Biotechnology stock FAQ
What happened to Unity Biotechnology stock?
Unity Biotechnology was delisted from the Nasdaq in July 2025. The final close was $0.16 on July 9, 2025.
Can I still buy UBX stock?
No. UBX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on July 9, 2025.
What was the last price of UBX?
UBX last closed at $0.16 on July 9, 2025, which valued the company at about $2.75M.
How did Unity Biotechnology do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Unity Biotechnology reported revenue of $0.00 and net income of −$26.0M.
When did Unity Biotechnology go public?
Unity Biotechnology shares started trading on May 3, 2018.
UBX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.